Abstract
Olanzapine is an atypical antipsychotic with proven efficacy in the treatment of schizophrenia and bipolar disorder. This molecule is known for its metabolic side effects, but it is considered the safest with regard to haematological toxicity. The case of our 28 year old patient, who has been followed anarchically for 5 years for schizophrenia and who presented a thrombocytopenia of 99,000/mm3 within a week of being put on olanzapine without any other associated signs, is one of nine cases published in the literature illustrating this association which is rare but encourages clinicians to institute close haematological monitoring to prevent any life threatening effects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
